Semi-Annual Consolidated Statement Of Cash Flows

KYORIN Pharmaceutical Co., Ltd. - Filing #7558629

Concept As at
2023-03-31
2022-04-01 to
2023-03-31
2021-04-01 to
2022-03-31
As at
2022-03-31
As at
2021-03-31
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
216,000,000 JPY
7,240,000,000 JPY
Interest and dividends received
473,000,000 JPY
420,000,000 JPY
Interest paid
-66,000,000 JPY
-66,000,000 JPY
Income taxes paid
-2,065,000,000 JPY
-1,248,000,000 JPY
Net cash provided by (used in) operating activities
2,008,000,000 JPY
6,346,000,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-6,330,000,000 JPY
-2,444,000,000 JPY
Proceeds from sale of property, plant and equipment
100,000,000 JPY
0 JPY
Purchase of investment securities
-100,000,000 JPY
-3,407,000,000 JPY
Other, net
-251,000,000 JPY
-185,000,000 JPY
Net cash provided by (used in) investing activities
-6,275,000,000 JPY
-2,560,000,000 JPY
Cash flows from financing activities
Repayments of long-term borrowings
-200,000,000 JPY
-200,000,000 JPY
Dividends paid
-3,015,000,000 JPY
-3,767,000,000 JPY
Net cash provided by (used in) financing activities
-3,363,000,000 JPY
-4,112,000,000 JPY
Effect of exchange rate change on cash and cash equivalents
241,000,000 JPY
139,000,000 JPY
Net increase (decrease) in cash and cash equivalents
-7,388,000,000 JPY
-186,000,000 JPY
Cash and cash equivalents
18,816,000,000 JPY
26,289,000,000 JPY
26,476,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.